Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Telix Pharma | Sydney | Healthcare | Biotechnology & Medical Research | $6.46B | 194.9x | 1.49 | $19.32 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Neuren Pharma | Sydney | Healthcare | Biotechnology & Medical Research | $2.59B | 16.4x | 0 | $20.17 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Clarity Pharmaceuticals | Sydney | Healthcare | Biotechnology & Medical Research | $1.96B | -42.2x | 1.46 | $6.13 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Mesoblast | Sydney | Healthcare | Biotechnology & Medical Research | $1.29B | -8.1x | -0.49 | $1.13 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Opthea | Sydney | Healthcare | Biotechnology & Medical Research | $517.06M | -0.8x | -1.99 | $0.41 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
PYC Therapeutics Ltd | Sydney | Healthcare | Biotechnology & Medical Research | $489.94M | -17.5x | -1.27 | $0.10 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Immutep | Sydney | Healthcare | Biotechnology & Medical Research | $474.37M | -8.5x | -1.23 | $0.34 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Imugene Ltd | Sydney | Healthcare | Biotechnology & Medical Research | $404.21M | -4.3x | 0.05 | $0.05 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Race Oncology | Sydney | Healthcare | Biotechnology & Medical Research | $281.09M | -24.4x | 11 | $1.61 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Dimerix | Sydney | Healthcare | Biotechnology & Medical Research | $260.26M | -15.8x | -0.91 | $0.47 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Actinogen Medical | Sydney | Healthcare | Biotechnology & Medical Research | $229.42M | -10.6x | 0.53 | $0.09 | 6.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
CogState Ltd | Sydney | Healthcare | Biotechnology & Medical Research | $216.04M | 27.6x | 0.4 | $1.26 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Arovella Therapeutics | Sydney | Healthcare | Biotechnology & Medical Research | $176.61M | -14x | -2.54 | $0.17 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Proteomics Intl Labs | Sydney | Healthcare | Biotechnology & Medical Research | $119.21M | -17.2x | 2.42 | $0.91 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
LTR Pharma | Sydney | Healthcare | Biotechnology & Medical Research | $108.75M | $0.88 | 12.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Argenica Therapeutics | Sydney | Healthcare | Biotechnology & Medical Research | $95.87M | -17.6x | 7.12 | $0.81 | 4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Paradigm Biopharmaceuticals Ltd | Sydney | Healthcare | Biotechnology & Medical Research | $91.09M | -1.1x | 0.03 | $0.26 | -3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Orthocell Ltd | Sydney | Healthcare | Biotechnology & Medical Research | $82.68M | -10.5x | -0.68 | $0.38 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
AVITA Medical | Sydney | Healthcare | Biotechnology & Medical Research | $80.31M | -1.2x | 0.08 | $3.14 | 4.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Pacific Edge | Sydney | Healthcare | Biotechnology & Medical Research | $68.59M | -2.6x | 0.25 | $0.08 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Percheron Therapeutics | Sydney | Healthcare | Biotechnology & Medical Research | $66.71M | -4.6x | 0.23 | $0.08 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Inoviq | Sydney | Healthcare | Biotechnology & Medical Research | $66.17M | -8.4x | -0.15 | $0.59 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
IDT Australia Ltd | Sydney | Healthcare | Biotechnology & Medical Research | $55.85M | -5.9x | -0.25 | $0.13 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Anteo Diagnostics | Sydney | Healthcare | Biotechnology & Medical Research | $51.83M | -4.2x | 1.61 | $0.02 | 4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Cynata Therapeutics Ltd | Sydney | Healthcare | Biotechnology & Medical Research | $44.91M | -3x | 0.13 | $0.25 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Prescient Therapeutics Ltd | Sydney | Healthcare | Biotechnology & Medical Research | $34.63M | -4.3x | 0.2 | $0.04 | -4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Tryptamine Therapeutics | Sydney | Healthcare | Biotechnology & Medical Research | $30.74M | -0.4x | -0.25 | $0.02 | -4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Oncosil Medical Ltd | Sydney | Healthcare | Biotechnology & Medical Research | $30.58M | -1.3x | -0.07 | $0.009 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Biotron Ltd | Sydney | Healthcare | Biotechnology & Medical Research | $29.78M | -8.3x | 0.08 | $0.03 | 6.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Invion Ltd | Sydney | Healthcare | Biotechnology & Medical Research | $26.42M | -14.2x | -1.21 | $0.004 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |